1.67
+0.1(+6.37%)
Currency In USD
| Previous Close | 1.57 |
| Open | 1.57 |
| Day High | 1.67 |
| Day Low | 1.53 |
| 52-Week High | 7.92 |
| 52-Week Low | 1.53 |
| Volume | 70,745 |
| Average Volume | 1.37M |
| Market Cap | 18.01M |
| PE | -0.89 |
| EPS | -1.87 |
| Moving Average 50 Days | 2.54 |
| Moving Average 200 Days | 4.52 |
| Change | 0.1 |
If you invested $1000 in Serina Therapeutics, Inc. (SER) since IPO date, it would be worth $16.79 as of February 24, 2026 at a share price of $1.625. Whereas If you bought $1000 worth of Serina Therapeutics, Inc. (SER) shares 5 years ago, it would be worth $20.22 as of February 24, 2026 at a share price of $1.625.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
GlobeNewswire Inc.
3 hours ago
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient development strategy leveraging
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
GlobeNewswire Inc.
Feb 19, 2026 11:00 AM GMT
- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for first patient dosing in the first quarter of 2026
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
GlobeNewswire Inc.
Feb 03, 2026 11:00 AM GMT
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences" Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and in